AR085758A1 - Antidotos anticoagulantes - Google Patents

Antidotos anticoagulantes

Info

Publication number
AR085758A1
AR085758A1 ARP120101085A ARP120101085A AR085758A1 AR 085758 A1 AR085758 A1 AR 085758A1 AR P120101085 A ARP120101085 A AR P120101085A AR P120101085 A ARP120101085 A AR P120101085A AR 085758 A1 AR085758 A1 AR 085758A1
Authority
AR
Argentina
Prior art keywords
seq
group
antidotes
anticoagulant
variable domain
Prior art date
Application number
ARP120101085A
Other languages
English (en)
Inventor
Van Ryn Joanne
Canada Keith
Copenhaver Robert
Hauel Norbert
Litzenburger Tobias
Ronald Sarko Christopher
Singh Sanjaya
K Waterman Alisa
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45876804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR085758(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR085758A1 publication Critical patent/AR085758A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Moléculas de anticuerpo contra anticoagulantes, en particular dabigatran, y su uso como antídotos de dichos anticoagulantes. Reivindicación 1: Una molécula de anticuerpo de dabigatran caracterizada porque comprende un dominio variable de la cadena pesada con una CDR1 seleccionada del grupo que consiste en SEQ ID Nº 1, 7, 13, 19, 25, 31, 37, 43, 49, 55, 61 y 67, una CDR2 seleccionada del grupo que consiste en SEQ ID Nº 2, 8, 14, 20, 26, 32, 38, 44, 50, 56, 62 y 68, y una CDR3 seleccionada del grupo que consiste en SEQ ID Nº 3, 9, 15, 21, 27, 33, 39, 45, 51, 57 y 63, y un dominio variable de la cadena liviana con una CDR1 seleccionada del grupo que consiste en SEQ ID Nº 4, 10, 16, 22, 28, 34, 40, 46, 52, 58 y 64, una CDR2 seleccionada del grupo que consiste en SEQ ID Nº 5, 11, 17, 23, 29, 35, 41, 47, 53, 59 y 65, y una CDR3 seleccionada del grupo que consiste en SEQ ID Nº 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66 y 69.
ARP120101085A 2011-03-30 2012-03-29 Antidotos anticoagulantes AR085758A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161469207P 2011-03-30 2011-03-30

Publications (1)

Publication Number Publication Date
AR085758A1 true AR085758A1 (es) 2013-10-23

Family

ID=45876804

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101085A AR085758A1 (es) 2011-03-30 2012-03-29 Antidotos anticoagulantes

Country Status (22)

Country Link
US (2) US8821871B2 (es)
EP (1) EP2691156A1 (es)
JP (1) JP2014515740A (es)
KR (1) KR20140009437A (es)
CN (1) CN103476459A (es)
AP (1) AP2013007046A0 (es)
AR (1) AR085758A1 (es)
BR (1) BR112013025031A2 (es)
CA (1) CA2827787A1 (es)
CL (1) CL2013002551A1 (es)
CO (1) CO6771448A2 (es)
EA (1) EA201301090A1 (es)
EC (1) ECSP13012997A (es)
IL (1) IL227653A0 (es)
MA (1) MA34978B1 (es)
MX (1) MX2013011092A (es)
PE (1) PE20140964A1 (es)
SG (1) SG193552A1 (es)
TN (1) TN2013000388A1 (es)
TW (1) TW201302796A (es)
UY (1) UY33994A (es)
WO (1) WO2012130834A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2865068T3 (es) 2011-01-14 2021-10-14 Univ California Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos
UA116336C2 (uk) 2011-11-29 2018-03-12 Перосфіе Фармасьютікалз Інк. Агенти, реверсуючі дію антикоагулянтів
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
MX368625B (es) * 2013-07-30 2019-10-08 Janssen Sciences Ireland Uc Derivados de tieno[3,2-d]pirimidinas para el tratamiento de infecciones virales.
KR101523503B1 (ko) * 2013-09-17 2015-05-29 강원대학교산학협력단 아디포넥틴으로부터 유래한 펩타이드 및 이를 포함하는 조성물
EP3060583A1 (en) 2013-10-25 2016-08-31 Boehringer Ingelheim International GmbH Anticoagulant antidotes
EP2980218A1 (en) * 2014-07-30 2016-02-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors
WO2019210270A2 (en) * 2018-04-27 2019-10-31 Seattle Children's Hospital D/B/A Seattle Children's Research Institute In vivo gene therapy using delivery of a lentiviral gene construct

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ATE151113T1 (de) 1992-01-23 1997-04-15 Merck Patent Gmbh Fusionsproteine von monomeren und dimeren von antikörperfragmenten
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
PT1498427E (pt) 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
DK0701571T3 (da) 1993-06-03 1997-09-15 Therapeutic Antibodies Inc Antistoffragmenter til terapi
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
CA2288994C (en) 1997-04-30 2011-07-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US6440417B1 (en) 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US20040010134A1 (en) 2000-04-12 2004-01-15 Rosen Craig A. Albumin fusion proteins
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
EP2706116A1 (en) 2001-01-17 2014-03-12 Emergent Product Development Seattle, LLC Binding domain-immunoglobulin fusion proteins
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
JP2006512895A (ja) 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
EP2390268B1 (en) 2002-11-08 2017-11-01 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
ATE414106T1 (de) 2003-06-30 2008-11-15 Domantis Ltd Pegylierte single-domain-antikörper (dab)
CA2697583C (en) 2007-09-28 2016-04-12 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
AU2010288601A1 (en) * 2009-08-24 2012-02-02 Boehringer Ingelheim International Gmbh Emergency interventions of active charcoal with dabigatran etexilate overdosing
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante

Also Published As

Publication number Publication date
CO6771448A2 (es) 2013-10-15
MA34978B1 (fr) 2014-03-01
SG193552A1 (en) 2013-11-29
CL2013002551A1 (es) 2014-02-14
NZ613543A (en) 2015-07-31
ECSP13012997A (es) 2013-12-31
UY33994A (es) 2012-09-28
MX2013011092A (es) 2013-12-06
US8821871B2 (en) 2014-09-02
EA201301090A1 (ru) 2014-05-30
IL227653A0 (en) 2013-09-30
BR112013025031A2 (pt) 2017-08-01
AP2013007046A0 (en) 2013-08-31
TN2013000388A1 (en) 2015-01-20
PE20140964A1 (es) 2014-08-17
WO2012130834A1 (en) 2012-10-04
CA2827787A1 (en) 2012-10-04
CN103476459A (zh) 2013-12-25
TW201302796A (zh) 2013-01-16
US20120276123A1 (en) 2012-11-01
JP2014515740A (ja) 2014-07-03
KR20140009437A (ko) 2014-01-22
EP2691156A1 (en) 2014-02-05
US20140377265A1 (en) 2014-12-25

Similar Documents

Publication Publication Date Title
AR085758A1 (es) Antidotos anticoagulantes
CY1121497T1 (el) Συριγγα
TN2012000366A1 (en) Anticoagulant antidotes
EA201590174A1 (ru) Иммуноконъюгаты, содержащие анти-cd22 антитела
AR117911A2 (es) Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
CY1118885T1 (el) Συνθετικες πεπτιδογλυκανες που δεσμευουν υαλουρονικο οξυ, παρασκευη, και μεθοδοι χρησης
DOP2016000252A (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
MX2022014125A (es) Anticuerpos y conjugados de los mismos.
CR20160425A (es) Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas
EA201590173A1 (ru) Иммуноконъюгаты, содержащие антитела к cd22
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201691488A1 (ru) Молекулы антител против pd-1 и их применения
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
BR112017007379A2 (pt) moléculas de anticorpo para pd-l1 e usos das mesmas
PH12015500196A1 (en) Methods of treating a tauopathy
EA201300978A1 (ru) Антитела к сеа
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
BR112016020518A2 (pt) receptor antigênico quimérico
CO7151527A2 (es) Anticuerpos anti-cd79 b e inmunoconjugados
CL2014001640A1 (es) Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo.
BR112014030278A2 (pt) anticorpo, e, composição.
CR20140441A (es) Anticuerpos anti-lgr5 e inmunoconjugados
AR084315A1 (es) Anticuerpos anti-notch1
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion

Legal Events

Date Code Title Description
FB Suspension of granting procedure